Want to see VSTM full AI Analyst Report?
VSTM Stock Chart & Stats
$7.08
-$0.13(-2.10%)
At close: 4:00 PM EDT
$7.08
-$0.13(-2.10%)
Day’s Range― - ―
52-Week Range$3.43 - $10.82
Previous CloseN/A
Volume2.53M
Average Volume (3M)4.24M
Market Cap
$1.05B
Enterprise Value$330.42M
Total Cash (Recent Filing)$136.35M
Total Debt (Recent Filing)$84.33M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 11, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.46
Shares Outstanding121,500,940
10 Day Avg. Volume7,967,527
30 Day Avg. Volume4,244,021
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)9.35
Price to Sales (P/S)17.31
P/FCF Ratio-3.89
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue3.78
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$18.17Price Target Upside156.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.63
Revenue Forecast (FY)$113.48M
Bulls Say, Bears Say
Bulls Say
Commercial Traction And Path To Self-fundingGrowing product revenue and management’s self-sustaining LGSOC outlook indicate that the commercial franchise is moving toward supporting its own operations and development costs. If achieved, this could reduce dependence on capital markets while creating a durable funding base for pipeline investment.
Promising Pipeline And Regulatory AdvancementEarly response data across multiple KRAS G12D-driven tumors, combined with FDA alignment on a first-line pancreatic cancer Phase 3 trial, materially advances the pipeline. These developments expand potential indications and provide defined clinical milestones that could support future commercialization.
Strengthened LiquidityA substantial capital raise improves near-term liquidity and gives Verastem additional resources to fund clinical execution, commercialization, and strategic initiatives. Greater financial capacity can help the company reach important readouts without immediately depending on another financing event.
Bears Say
Severe Losses And Cash BurnThe company is not currently self-funding: operating and free cash flow remain deeply negative while net losses are very large relative to revenue. Continued spending at this scale requires sustained financing or rapid commercial improvement, making execution and liquidity important ongoing risks.
Leverage And Secured Financing ObligationsMeaningful leverage limits financial flexibility while the business remains loss-making. Senior secured, product-linked financing also creates repayment and revenue-sharing obligations, potentially constraining future cash allocation and increasing pressure on commercialization to fund development.
Clinical, Competitive, And Regulatory Execution RiskThe pipeline’s value depends on differentiating VS-7375 in an active field and satisfying evolving regulatory standards. GI tolerability issues and dose interruptions may affect adherence and durability, while competitive pressure could make approval, adoption, and commercial execution less predictable.
Verastem News
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $3.43 and its highest was $10.82 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $1.05B.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Nov 11, 2026 which is in 20 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Aug 06, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.08.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.47.
How many shares outstanding does Verastem have?
Verastem has 121,500,940 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went up 14.044%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verastem Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.17 (156.59% Upside)
$18.17 (156.59% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 86%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.45%
12-Months-Change
Fundamentals
Return on Equity
-467.49%
Trailing 12-Months
Asset Growth
5.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Verastem
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
VSTM Company Deck
VSTM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: commercial rebound with $25.1M in product revenue, strengthened liquidity via a $50M draw and $15M milestone (pro forma cash $201.4M), improved non-GAAP loss versus prior year, and rapid clinical progress for VS-7375 (enrollment completed in expansions, Fast Track for NSCLC, three Phase II studies initiated and an October data update anticipated). Notable risks remain — the company is still loss-making with high R&D spend, relies on financing to bridge to readouts, has limited prescription visibility, faces tolerability and dose-management operational challenges, and navigates a competitive/regulatory landscape. On balance, the material commercial and clinical achievements and improved financial cushion outweigh the outstanding challenges.View all VSTM earnings summariesVSTM Stock 12 Month Forecast
Average Price Target
$18.17
▲(156.59% Upside)
Technical Analysis
Puma Biotechnology
―
CytomX Therapeutics
―
Arvinas Holding Company
―
Allogene Therapeutics
―
BridgeBio Oncology Therapeutics
―
Ownership Overview
1.08% Insiders
5.76% Mutual Funds
0.58% Other Institutional Investors
82.47% Public Companies and
Individual Investors